Close

Ultragenyx Pharmaceutical (RARE) Reports Interim Data From Phase 2 Extension Study of Sialic Acid

October 13, 2014 9:02 AM EDT Send to a Friend
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login